A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets.

“We believe IceCure’s commitment to technology innovation and our drive to make a significant impact on patient outcomes has resulted in our intellectual property portfolio in cryoablation reaching 55 patents granted and allowed across the globe,” said Eyal Shamir, IceCure’s Chief Executive Officer. “Our cryoablation systems and probes already have regulatory approval in China for indications including breast cancer, and we continue to innovate next-generation liquid nitrogen-based systems including XSense™ to further improve patient outcomes.”

The notice of allowance for the patent addresses precise temperature control, which is crucial for efficacy and tissue safety in cryoablation procedures. Cryogenic flow control achieves this by utilizing sensor data to regulate the flow of cryogens, ensuring the desired temperature is reached and maintained at the distal tip of catheters and probes. This optimized cryogenic delivery enhances treatment effectiveness in cryoablation procedures. Advanced cryogen flow control systems may also offer functionalities, such as navigation and mapping support within the patient’s anatomy, and be incorporated into a wide range of cryosurgical tools.